NeoGenomics, Inc. (NEO) has seen some recent volatility in the market and its shares finished trading at $26.91 yesterday. People are starting to take interest of NEO as the shares traded as high as $28.40 and as low as $26.84 in the last market trading day.

NeoGenomics, Inc. (NEO) average trading volume is 1.10M. However, in the last market trading day NeoGenomics, Inc. (NEO) traded 844,772 shares. The first support level on NEO is $25.86 and the first resistance level on NEO is $34.52. NEO 50-day moving average is $27.38 and NEO 200-day moving average is $27.91.

NeoGenomics, Inc. (NEO) recent performance has been specified by the recent movement in NEO shares. NEO has performed -2.41% over the past 4 weeks, NEO has performed -19.53% over the past quarter and NEO has shown 21.08% over the past 1 year. NeoGenomics, Inc. (NEO) has a 12 month range of $18.52 to $34.97. NeoGenomics, Inc. (NEO) is trading 45.28% from its 12 month low and -23.05% from its 12 month high. NeoGenomics, Inc. (NEO) is indicating a 4.89% short float indicating the amount short in the float.

NEO has 107.92M shares outstanding and 103.34M shares in the float. NeoGenomics, Inc. (NEO) presently has a market cap of $2.90B and income of $3.50M. The EPS next quarter for NEO is -0.09 and projected EPS net year is 3600.00%. The market cap of NeoGenomics, Inc. (NEO) at $2.90B signifies how many People own shares of NEO and is based off the last price ($26.91) of NEO and the amount of shares outstanding (107.92M) with NeoGenomics, Inc. (NEO).

NeoGenomics, Inc. (NEO) has total cash (mrq) of 86.25M, total cash per share (mrq) of 0.82, total debt of NEO is at 156.69M and total debt/equity (mrq) is 31.02. NeoGenomics, Inc. (NEO) running cash flow (ttm) is 10.34M and NEO leveraged free cash flow (ttm) is -3.65M.

NEO is trading -4.40% below (bearish) its SMA20, -1.09% below (bearish) its SMA50 and 2.69% above (bullish) its SMA200.

Recent News:

In recent news, on May 11, 2020, it was announced, NeoGenomics To Virtually Participate In Fireside Chat At BofA Securities 2020 Health Care Conference. In this news it stated, NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Bill Bonello, President Informatics Division, Director of Investor Relations, will be participating in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 3:40pm ET. The presentation will be webcast live and accessible online via the investors section of the Company’s website, www.neogenomics.com. A replay of the webcast will be archived for 90 days following the presentation.

About NeoGenomics, Inc. (NEO):

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.